Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

  • In development
  • GID-TA10620
  • Expected publication date: 

Documents

Documents created during the development process.

Final draft guidance

Declaration of interests

Draft guidance

Declaration of interests

Committee meetings

  • Committee meeting: 1

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3753

Notes